Helen Thackray

Dr. Thackray became a director in October 2026.  She has over 25 years of biotechnology leadershipexperience in rare disease and oncology drug development, ranging frompreclinical start-ups to a mature public company with $2B market cap and three approvedproducts. Most recently, she served as the Chief Research and DevelopmentOfficer at BioCryst Pharmaceuticals where she oversaw R&D, regulatoryaffairs, medical affairs, and portfolio strategy. Prior to BioCryst, she heldsenior leadership positions at GlycoMimetics Inc. (2006-2021) including SeniorVice President of Clinical Development and Chief Medical Officer. Dr. Thackraycurrently serves as a director of Eupraxia Pharmaceuticals and she recentlyserved as a director of  BioCryst andImmunoGen (acquired by AbbVie), both public companies transitioning fromclinical to commercial stage during her tenure. She is a board-certifiedpediatrician, serving on the faculty of the Children’s National Medical Centerand George Washington University School of Medicine and Health Sciences (2000-2025). Dr. Thackrayholds a Bachelor of Science degree in biological sciences from StanfordUniversity, an M.D. from George Washington University, and has authored morethan 60 peer-reviewed articles and presentations. She completed her pediatricresidency and chief residency at Children’s National Medical Center, trained inmedical genetics at the National Human Genome Research Institute at theNational Institutes of Health, and is a Fellow of the American Academy ofPediatrics (FAAP).

‍